Download PDF
Onkologische Welt 2024; 15(05): 308-309
DOI: 10.1055/a-2348-1777
Kongressnachlese

CAR-T-Zellen als Präzisionstherapie der Zukunft

Gastrointestinale Tumoren
Alexander Kretzschmar∗
1   München
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Mit den CAR-T-Zell-Therapien ist die Präzisionsmedizin auch bei den soliden gastrointestinalen Tumoren angekommen. Auf dem ASCO 2024 wurden mehrere Studien mit innovativen Kandidaten und therapeutischen Zielsubstraten vorgestellt.



Publication History

Article published online:
03 September 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Zhang C, Wang Z, Yang Z. et al Phase I escalating-dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers.. Mol Ther 2017; 25 (05) 1248-1258
    CrossrefPubMedGoogle Scholar
  • 2 Zhu X, Chen J, Li W. et al Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors.. Cancer Res 2024; 84 (01) 84-100
    CrossrefPubMedGoogle Scholar
  • 3 Zhang H. et al Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. J Clin Oncol. 2024; 42. 16 Abstract 3514
    Google Scholar
  • 4 Qian S, Chen J, Zhao Y. et al Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.. Cytotherapy 2024; 26 (02) 113-125
    CrossrefPubMedGoogle Scholar
  • 5 Zhang Q. et al Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2024; 42. 16 Abstract 4019
    Google Scholar
  • 6 Luo T. et al Efficacy of EpCAM CAR-T IMC001 in advanced gastric cancers. J Clin Oncol. 2024; 42. 16 Abstract 4043
    Google Scholar